MacroGenics | MGNX - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Geron USD 570.54M 3.16M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Merck USD 128.68B 8.18B 2026-03
Pfizer USD 207.62B 542M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Xencor USD 875.5M 6.68M 2025-12